.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Global Updates in Advanced Gastric Cancer from ESMO 2020

EP. 1: Global Trends in Gastric Cancers

October 22nd 2020

EP. 2: Optimal Approach Toward Advanced Gastric Cancers in US

October 22nd 2020

EP. 3: Frontline Treatment in Metastatic Gastric Cancer

October 22nd 2020

EP. 4: Treatment Landscape in Gastric Cancers Pre-ESMO 2020

October 22nd 2020

EP. 5: First-Line I/O Successful in Gastric Adenocarcinoma

October 22nd 2020

EP. 6: ESMO 2020: Practice-Changing Data in Esophageal Cancer

October 22nd 2020

EP. 7: Applying New Data in the Real-World for GEJ Cancer

October 22nd 2020

EP. 8: Predicting Response With Biomarkers in Gastric Cancers

October 22nd 2020

EP. 9: Clinical Rationale for Antiangiogenics in Gastric Cancer

October 22nd 2020

EP. 10: Toxicity Management in Second Line for Gastric Cancer

October 22nd 2020

EP. 11: Looking Toward the Future in Gastroesophageal Cancer

October 22nd 2020

EP. 12: Adjuvant Treatment in Gastroesophageal Cancer

October 22nd 2020

EP. 13: Maintenance Therapy in Gastric Cancers

October 22nd 2020

EP. 14: VEGFR TKIs in Gastroesophageal Cancer

October 22nd 2020

EP. 15: Emerging Approaches in HER2+ Gastric Cancers

October 22nd 2020

EP. 16: Applying Data to the Real World in Gastric Cancer

October 22nd 2020